{"pmid":32438450,"title":"IL-1 blockade with anakinra in acute leukaemia patients with severe COVID-19 pneumonia appears safe and may result in clinical improvement.","text":["IL-1 blockade with anakinra in acute leukaemia patients with severe COVID-19 pneumonia appears safe and may result in clinical improvement.","As of 17th May, 2020 the number of patients infected by coronavirus disease 2019 (COVID-19) worldwide has exceeded 4.5 million (WHO 2020). A subgroup of patients with COVID-19 pneumonia develop a hyperinflammatory syndrome which has a similar cytokine release profile to secondary haemophagocytic lymphohistiocytosis (HLH) (Huang, et al 2020). Immunomodulatory drugs are hypothesised to abrogate the dysfunctional immune response in hyperinflammatory COVID-19 and are currently being investigated in clinical trials. IL-1 blockage with anakinra has been shown to be safe and is associated with clinical improvement in patients with hyperinflammatory COVID-19 (Cavalli, et al 2020).","Br J Haematol","Day, James W","Fox, Thomas A","Halsey, Richard","Carpenter, Ben","Kottaridis, Panagiotis D","32438450"],"abstract":["As of 17th May, 2020 the number of patients infected by coronavirus disease 2019 (COVID-19) worldwide has exceeded 4.5 million (WHO 2020). A subgroup of patients with COVID-19 pneumonia develop a hyperinflammatory syndrome which has a similar cytokine release profile to secondary haemophagocytic lymphohistiocytosis (HLH) (Huang, et al 2020). Immunomodulatory drugs are hypothesised to abrogate the dysfunctional immune response in hyperinflammatory COVID-19 and are currently being investigated in clinical trials. IL-1 blockage with anakinra has been shown to be safe and is associated with clinical improvement in patients with hyperinflammatory COVID-19 (Cavalli, et al 2020)."],"journal":"Br J Haematol","authors":["Day, James W","Fox, Thomas A","Halsey, Richard","Carpenter, Ben","Kottaridis, Panagiotis D"],"date":"2020-05-22T11:00:00Z","year":2020,"_id":"32438450","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1111/bjh.16873","topics":["Treatment"],"weight":1,"_version_":1667521393665769472,"score":9.490897,"similar":[{"pmid":32437934,"title":"Use of anakinra in severe COVID-19: a case report.","text":["Use of anakinra in severe COVID-19: a case report.","Coronavirus Disease 19 is a global healthcare emergency with high lethality rate. Relevant inflammatory cytokine storm is associated with severity of disease and IL1 inhibition is a cornerstone treatment for hyperinflammatory diseases. We present here the case of a patient with critical COVID-19 successfully treated with IL-1 receptor antagonist (anakinra).","Int J Infect Dis","Filocamo, Giovanni","Mangioni, Davide","Tagliabue, Paola","Aliberti, Stefano","Costantino, Giorgio","Minoia, Francesca","Bandera, Alessandra","32437934"],"abstract":["Coronavirus Disease 19 is a global healthcare emergency with high lethality rate. Relevant inflammatory cytokine storm is associated with severity of disease and IL1 inhibition is a cornerstone treatment for hyperinflammatory diseases. We present here the case of a patient with critical COVID-19 successfully treated with IL-1 receptor antagonist (anakinra)."],"journal":"Int J Infect Dis","authors":["Filocamo, Giovanni","Mangioni, Davide","Tagliabue, Paola","Aliberti, Stefano","Costantino, Giorgio","Minoia, Francesca","Bandera, Alessandra"],"date":"2020-05-22T11:00:00Z","year":2020,"_id":"32437934","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1016/j.ijid.2020.05.026","keywords":["anakinra","biologic","covid-19","il-1","treatment"],"topics":["Case Report"],"weight":1,"_version_":1667521393551474689,"score":207.67172},{"pmid":32416415,"title":"Etoposide-based therapy for severe forms of COVID-19.","text":["Etoposide-based therapy for severe forms of COVID-19.","The new coronavirus infection COVID-19 has quickly become a global health emergency. Mortality is principally due to severe Acute Respiratory Distress Syndrome (ARDS) which relays only on supportive treatment. Numerous pathological, clinical and laboratory findings rise the similarity between moderate to severe COVID-19 and haemophagocytic lymphohistiocytosis (HLH). Etoposide-based protocol including dexametasone is the standard of care for secondary HLH. The protocol has been successfully used in HLHs that are secondary to EBV and H1N1 infections by inducing complete response and prolonged survival. These observations prompt to consider this cytotoxic therapy in HLH associated to moderately severe to severe forms of COVID-19.","Med Hypotheses","Hamizi, Kamel","Aouidane, Souhila","Belaaloui, Ghania","32416415"],"abstract":["The new coronavirus infection COVID-19 has quickly become a global health emergency. Mortality is principally due to severe Acute Respiratory Distress Syndrome (ARDS) which relays only on supportive treatment. Numerous pathological, clinical and laboratory findings rise the similarity between moderate to severe COVID-19 and haemophagocytic lymphohistiocytosis (HLH). Etoposide-based protocol including dexametasone is the standard of care for secondary HLH. The protocol has been successfully used in HLHs that are secondary to EBV and H1N1 infections by inducing complete response and prolonged survival. These observations prompt to consider this cytotoxic therapy in HLH associated to moderately severe to severe forms of COVID-19."],"journal":"Med Hypotheses","authors":["Hamizi, Kamel","Aouidane, Souhila","Belaaloui, Ghania"],"date":"2020-05-17T11:00:00Z","year":2020,"_id":"32416415","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1016/j.mehy.2020.109826","keywords":["covid-19","etoposide","hlh","haemophagocytic lymphohistiocytosis"],"topics":["Treatment"],"weight":1,"_version_":1666991242661068800,"score":168.80437},{"pmid":32480422,"title":"Interleukin-6 Blockade Treatment for COVID-19 associated Cytokine Release Syndrome in a Patient with Poorly Controlled Chronic Myeloid Leukaemia.","text":["Interleukin-6 Blockade Treatment for COVID-19 associated Cytokine Release Syndrome in a Patient with Poorly Controlled Chronic Myeloid Leukaemia.","In December 2019, a novel coronavirus pneumonia, coronavirus disease 2019 (COVID-19), caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) was reported in Wuhan, China. A hyperinflammatory immune response, or cytokine release syndrome (CRS) is observed in critically unwell patients with SARS-CoV-2 globally. Severe lymphopenia, hyperactivated pro-inflammatory T cells(1) and decreased regulatory T cells(2) are seen in these critically ill patients, suggesting dysregulated immune responses.","Br J Haematol","Ranger, Amita","Haji, Ruby","Kaczmarski, Richard","Danga, Akila","32480422"],"abstract":["In December 2019, a novel coronavirus pneumonia, coronavirus disease 2019 (COVID-19), caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) was reported in Wuhan, China. A hyperinflammatory immune response, or cytokine release syndrome (CRS) is observed in critically unwell patients with SARS-CoV-2 globally. Severe lymphopenia, hyperactivated pro-inflammatory T cells(1) and decreased regulatory T cells(2) are seen in these critically ill patients, suggesting dysregulated immune responses."],"journal":"Br J Haematol","authors":["Ranger, Amita","Haji, Ruby","Kaczmarski, Richard","Danga, Akila"],"date":"2020-06-02T11:00:00Z","year":2020,"_id":"32480422","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1111/bjh.16901","locations":["Wuhan","China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Case Report"],"weight":1,"_version_":1668532089511739393,"score":168.49037},{"pmid":32422376,"title":"Interleukin-1 receptor antagonist anakinra in association with remdesivir in severe Coronavirus disease 2019: A case report.","text":["Interleukin-1 receptor antagonist anakinra in association with remdesivir in severe Coronavirus disease 2019: A case report.","We report the first successful treatment with the IL-1 receptor antagonist anakinra, in association with the most promising and available antiviral therapy, of a severe case of novel coronavirus disease 2019 (COVID-19). We describe the diagnosis, clinical course, and management of the case, including the respiratory failure at presentation, the progression to a scenario characterized by profound inflammatory dysregulation similar to that observed during macrophage activation syndrome, and the clinical improvement after treatment with the IL-1 receptor antagonist anakinra. This case highlights the high tolerability and the interesting immunomodulatory profile of the IL-1 receptor antagonist anakinra in the setting of severe COVID-19 associated with remdesivir therapy. Further studies are needed to confirm the safety and efficacy of this combination strategy in the treatment of this emerging infection.","Int J Infect Dis","Franzetti, Marco","Pozzetti, Ugo","Carugati, Manuela","Pandolfo, Alessandro","Molteni, Chiara","Faccioli, Paolo","Castaldo, Gioacchino","Longoni, Ernesto","Ormas, Valentina","Iemoli, Enrico","Piconi, Stefania","32422376"],"abstract":["We report the first successful treatment with the IL-1 receptor antagonist anakinra, in association with the most promising and available antiviral therapy, of a severe case of novel coronavirus disease 2019 (COVID-19). We describe the diagnosis, clinical course, and management of the case, including the respiratory failure at presentation, the progression to a scenario characterized by profound inflammatory dysregulation similar to that observed during macrophage activation syndrome, and the clinical improvement after treatment with the IL-1 receptor antagonist anakinra. This case highlights the high tolerability and the interesting immunomodulatory profile of the IL-1 receptor antagonist anakinra in the setting of severe COVID-19 associated with remdesivir therapy. Further studies are needed to confirm the safety and efficacy of this combination strategy in the treatment of this emerging infection."],"journal":"Int J Infect Dis","authors":["Franzetti, Marco","Pozzetti, Ugo","Carugati, Manuela","Pandolfo, Alessandro","Molteni, Chiara","Faccioli, Paolo","Castaldo, Gioacchino","Longoni, Ernesto","Ormas, Valentina","Iemoli, Enrico","Piconi, Stefania"],"date":"2020-05-19T11:00:00Z","year":2020,"_id":"32422376","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1016/j.ijid.2020.05.050","keywords":["anakinra","cytokine-release syndrome","interleukin-1 receptor antagonist","novel coronavirus disease 2019 (covid-19)","remdesivir"],"topics":["Case Report"],"weight":1,"_version_":1667159284442464256,"score":160.27396},{"pmid":32267081,"title":"Continuous Intravenous Anakinra Infusion to Calm the Cytokine Storm in Macrophage Activation Syndrome.","text":["Continuous Intravenous Anakinra Infusion to Calm the Cytokine Storm in Macrophage Activation Syndrome.","OBJECTIVE: The objective of this study was to report the benefit of a therapeutic approach consisting of intravenous (IV) continuous anakinra (recombinant human interleukin-1 receptor antagonist) infusions in treating severely ill adult patients with secondary hemophagocytic lymphohistiocytosis or macrophage activation syndrome (MAS). METHODS: A retrospective chart review of five patients treated at Regions Hospital from 2016 to 2019 was conducted. Demographic, clinical, and laboratory characteristics and outcomes were recorded. RESULTS: Continuous IV anakinra infusions up to 2400 mg/d resulted in rapid serologic, then clinical response in 4 of 5 severely ill patients who were refractory to all other therapies, including subcutaneous anakinra. Subsequently, 3 of 5 patients have been maintained on anakinra or canakinumab, with no recurrence of MAS. CONCLUSION: Continuous infusion of IV anakinra may result in rapid serologic and subsequent clinical improvement in adult patients with MAS. This method for treating cytokine storm should be considered in the current COVID-19 pandemic in the subgroup of patients with severe disease who have a cytokine storm presentation.","ACR Open Rheumatol","Monteagudo, Luke Adam","Boothby, Aaron","Gertner, Elie","32267081"],"abstract":["OBJECTIVE: The objective of this study was to report the benefit of a therapeutic approach consisting of intravenous (IV) continuous anakinra (recombinant human interleukin-1 receptor antagonist) infusions in treating severely ill adult patients with secondary hemophagocytic lymphohistiocytosis or macrophage activation syndrome (MAS). METHODS: A retrospective chart review of five patients treated at Regions Hospital from 2016 to 2019 was conducted. Demographic, clinical, and laboratory characteristics and outcomes were recorded. RESULTS: Continuous IV anakinra infusions up to 2400 mg/d resulted in rapid serologic, then clinical response in 4 of 5 severely ill patients who were refractory to all other therapies, including subcutaneous anakinra. Subsequently, 3 of 5 patients have been maintained on anakinra or canakinumab, with no recurrence of MAS. CONCLUSION: Continuous infusion of IV anakinra may result in rapid serologic and subsequent clinical improvement in adult patients with MAS. This method for treating cytokine storm should be considered in the current COVID-19 pandemic in the subgroup of patients with severe disease who have a cytokine storm presentation."],"journal":"ACR Open Rheumatol","authors":["Monteagudo, Luke Adam","Boothby, Aaron","Gertner, Elie"],"date":"2020-04-09T11:00:00Z","year":2020,"_id":"32267081","source":"PubMed","week":"202015|Apr 06 - Apr 12","doi":"10.1002/acr2.11135","topics":["Treatment"],"weight":1,"_version_":1666138491984019456,"score":158.15077}]}